Topiramate monotherapy — Competitive Intelligence Brief

Topiramate monotherapy (Topiramate monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

marketed Anticonvulsant / Antiepileptic agent GABA-A receptor; voltage-gated sodium channels Neurology Small molecule

Target snapshot

Topiramate monotherapy (Topiramate monotherapy) — Johnson & Johnson Taiwan Ltd. Topiramate is an anticonvulsant that enhances GABA-mediated inhibition and blocks sodium channels to reduce neuronal excitability.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topiramate monotherapy TARGET	Topiramate monotherapy	Johnson & Johnson Taiwan Ltd	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Qudexy XR	Qudexy XR	Upsher-Smith Laboratories	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Topiramate-Implant	Topiramate-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor, sodium channels, glutamate receptors
Topiramate Standard	Topiramate Standard	Janssen Korea, Ltd., Korea	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
zonisamide low dose group	zonisamide low dose group	Eisai Korea Inc.	marketed	Anticonvulsant / Antiepileptic agent	Sodium channels, calcium channels, carbonic anhydrase
Low dose zonisamide	Low dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

1. University of Sao Paulo · 2 drugs in this class
2. Mario Negri Institute for Pharmacological Research · 2 drugs in this class
3. Janssen Korea, Ltd., Korea · 1 drug in this class
4. Johnson & Johnson Taiwan Ltd · 1 drug in this class
5. Ministry of Health and Sports, Myanmar · 1 drug in this class
6. Odense University Hospital · 1 drug in this class
7. UCB BIOSCIENCES GmbH · 1 drug in this class
8. University Hospitals Cleveland Medical Center · 1 drug in this class
9. Eisai Korea Inc. · 1 drug in this class
10. Upsher-Smith Laboratories · 1 drug in this class